Filing Details
- Accession Number:
- 0001415889-24-025575
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-10-23 17:10:53
- Reporting Period:
- 2024-10-21
- Accepted Time:
- 2024-10-23 17:10:53
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1800 | Abbott Laboratories | ABT | Pharmaceutical Preparations (2834) | 360698440 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1565916 | L Hubert Allen | 100 Abbott Park Road Abbott Park IL 60064 | Executive Vice President | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Shares Without Par Value | Acquisiton | 2024-10-21 | 157,421 | $47.00 | 342,227 | No | 4 | M | Direct | |
| Common Shares Without Par Value | Disposition | 2024-10-21 | 1,249 | $118.81 | 340,978 | No | 4 | S | Direct | |
| Common Shares Without Par Value | Disposition | 2024-10-21 | 5,901 | $118.15 | 335,077 | No | 4 | S | Direct | |
| Common Shares Without Par Value | Disposition | 2024-10-21 | 150,271 | $116.98 | 184,806 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Shares | Option (right to buy) | Disposition | 2024-10-21 | 157,421 | $0.00 | 157,421 | $47.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2018-02-20 | 2025-02-19 | No | 4 | M | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.68 to $118.92, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.68 to $118.59, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.68 to $117.64, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
Billionaire Hedge Funds
